These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35093895)

  • 1. Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal Tumours.
    Fauske L; Wærstad PH; Hompland I; Bruland ØS
    Anticancer Res; 2022 Feb; 42(2):955-963. PubMed ID: 35093895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study.
    Hompland I; Boye K; Wiedswang AM; Papakonstantinou A; Røsok B; Joensuu H; Bruland Ø
    Acta Oncol; 2024 May; 63():288-293. PubMed ID: 38712513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
    Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
    Fu Y; Hao H; Guo L; Yang G; Zhang X
    Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
    Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
    Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
    Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
    Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lichenoid drug eruption caused by imatinib mesylate in a Chinese patient with gastrointestinal stromal tumor.
    Luo JR; Xiang XJ; Xiong JP
    Int J Clin Pharmacol Ther; 2016 Sep; 54(9):719-22. PubMed ID: 27345285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Therapy of Gastrointestinal Stromal Tumors.
    Rutkowski P; Hompes D
    Surg Oncol Clin N Am; 2016 Oct; 25(4):735-59. PubMed ID: 27591496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST?
    Hompland I; Bruland ØS
    Anticancer Res; 2015 Nov; 35(11):5759-65. PubMed ID: 26503996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).
    Tang S; Yin Y; Shen C; Chen J; Yin X; Zhang B; Yao Y; Yang J; Chen Z
    World J Surg Oncol; 2017 Apr; 15(1):79. PubMed ID: 28399894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib.
    Jang BH; Kim BW; Lim KJ; Kim BG; Park SM; Kim JS; Ji JS; Choi H
    Korean J Gastroenterol; 2015 Jun; 65(6):366-9. PubMed ID: 26087692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
    JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
    Mohammadi M; Gelderblom H
    Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
    Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
    Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperpigmentation due to imatinib: A rare case of cutaneous involvement.
    Rehman H; Hakim N; Sugarman R; Seetharamu N; Saif MW
    J Oncol Pharm Pract; 2020 Sep; 26(6):1511-1515. PubMed ID: 32067560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
    Keung EZ; Fairweather M; Raut CP
    Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.
    Joensuu H
    Drugs; 2012 Oct; 72(15):1953-63. PubMed ID: 22994537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.
    Ben Ami E; Demetri GD
    Expert Opin Drug Saf; 2016; 15(4):571-8. PubMed ID: 26865352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Story of Imatinib in GIST - a Journey through the Development of a Targeted Therapy.
    Reichardt P
    Oncol Res Treat; 2018; 41(7-8):472-477. PubMed ID: 29895025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.